VEGFA and age-related macular degeneration: Even though anti-VEGF single chain antibody has shown some promise for the treatment of angiogenic-related diseases, such as age-related macular degeneration and tumor angiogenesis, effective endogenous anti-angiogenic molecules still have superb application prospects because they will not interfere with survival pathways.